Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development for Hypertension
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Globenewswire
- Strategic Collaboration: Orchestra BioMed's partnership with Medtronic aims to develop AVIM Therapy, which has received FDA Breakthrough Device Designation, potentially offering a new treatment option for 7.7 million U.S. patients with uncontrolled hypertension, significantly enhancing patient quality of life.
- Clinical Trial Progress: The MODERATO II study demonstrated that AVIM Therapy reduced 24-hour ambulatory systolic blood pressure by an average of 8.1 mmHg over six months, indicating its effectiveness in hypertension management and potentially opening up multi-billion-dollar market opportunities for the company.
- Innovative Product: The Virtue® Sirolimus AngioInfusion™ Balloon, as the first non-coated drug delivery system, has also received FDA Breakthrough Device Designation, aimed at treating coronary in-stent restenosis, which is expected to transform the treatment landscape for cardiovascular diseases.
- Market Potential: The successful development of AVIM Therapy and Virtue SAB will position Orchestra BioMed prominently in the global cardiovascular market, particularly in hypertension and atherosclerosis, driving long-term growth for the company.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 111.76 USD with a low forecast of 102.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 100.790
Low
102.00
Averages
111.76
High
120.00
Current: 100.790
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capital One Reports Disappointing Earnings and Acquires Brex
- Capital One Earnings Report: Capital One Financial Corporation reported fourth-quarter adjusted EPS results on January 22 that fell short of expectations, leading to a 7.6% drop in share price to $217.30, indicating market concerns over its profitability.
- Acquisition Announcement: The company announced plans to acquire Brex, aiming to expand its financial service offerings, which may pressure its financials in the short term but is expected to enhance competitive positioning in the long run.
- Medtronic Financial Health: Medtronic plc boasts substantial free cash flow and improving margins, with analysts maintaining an Outperform rating and raising the price target from $111 to $112, reflecting confidence in its future growth prospects.
- Caterpillar Stock Fluctuation: Despite analysts raising Caterpillar's price target from $675 to $702, the stock still fell 3.4% to $626.62, highlighting market divergence regarding its outlook.
Continue Reading
Minnesota CEOs Urge Immediate De-escalation After Fatal Shooting of Alex Pretti
- Business Leaders Unite: Over 60 CEOs from Minnesota-based companies signed a letter urging cooperation among state, local, and federal officials to address the tensions arising from immigration enforcement, highlighting the business community's urgent concern for social stability.
- Impact of Tragic Incident: The letter references the fatal shooting of Alex Pretti by federal immigration agents, which has resulted in 'widespread disruption and tragic loss of life,' reflecting the profound impact of the current situation on the community.
- Call for Leadership: The letter emphasizes ongoing communication with the Governor, the White House, and local mayors, indicating the proactive efforts of business leaders to push for solutions aimed at restoring normalcy in Minnesota.
- Political Tensions: While the letter does not mention President Trump, it notes the increased federal law enforcement presence has exacerbated tensions in Minnesota, with the business community seeking collaborative efforts to achieve a lasting resolution to foster economic recovery.
Continue Reading